CardioSource WorldNews - Page 24

ELIQUIS ® ( apixaban ) tablets , for oral use
Brief Summary of Prescribing Information . For complete prescribing information consult official package insert .
WARNING : ( A ) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS
( B ) SPINAL / EPIDURAL HEMATOMA
( A ) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS
Premature discontinuation of any oral anticoagulant , including ELIQUIS , increases the risk of thrombotic events . If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy , consider coverage with another anticoagulant [ see Dosage and Administration , Warnings and Precautions , and Clinical Studies ( 14.1 ) in full Prescribing Information ].
( B ) SPINAL / EPIDURAL HEMATOMA
Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture . These hematomas may result in long-term or permanent paralysis . Consider these risks when scheduling patients for spinal procedures . Factors that can increase the risk of developing epidural or spinal hematomas in these patients include :
• use of indwelling epidural catheters
• concomitant use of other drugs that affect hemostasis , such as nonsteroidal anti-inflammatory drugs ( NSAIDs ), platelet inhibitors , other anticoagulants
• a history of traumatic or repeated epidural or spinal punctures
• a history of spinal deformity or spinal surgery
• optimal timing between the administration of ELIQUIS and neuraxial procedures is not known
[ see Warnings and Precautions ]
Monitor patients frequently for signs and symptoms of neurological impairment . If neurological compromise is noted , urgent treatment is necessary [ see Warnings and Precautions ].
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [ see Warnings and Precautions ].
INDICATIONS AND USAGE
Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation — ELIQUIS ® ( apixaban ) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation .
Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery — ELIQUIS is indicated for the prophylaxis of deep vein thrombosis ( DVT ), which may lead to pulmonary embolism ( PE ), in patients who have undergone hip or knee replacement surgery .
Treatment of Deep Vein Thrombosis — ELIQUIS is indicated for the treatment of DVT . Treatment of Pulmonary Embolism — ELIQUIS is indicated for the treatment of PE .
Reduction in the Risk of Recurrence of DVT and PE — ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy .
DOSAGE AND ADMINISTRATION ( Selected information ) Temporary Interruption for Surgery and Other Interventions
ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding . ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled . Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required . ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established .( For complete Dosage and Administration section , see full Prescribing Information .)
CONTRAINDICATIONS ELIQUIS is contraindicated in patients with the following conditions :
• Active pathological bleeding [ see Warnings and Precautions and Adverse Reactions ]
• Severe hypersensitivity reaction to ELIQUIS ( e . g ., anaphylactic reactions ) [ see Adverse Reactions ]
WARNINGS AND PRECAUTIONS Increased Risk of Thrombotic Events after Premature Discontinuation
Premature discontinuation of any oral anticoagulant , including ELIQUIS , in the absence of adequate alternative anticoagulation increases the risk of thrombotic events . An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients . If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy , consider coverage with another anticoagulant [ see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.1 ) in full Prescribing Information ].
Bleeding
ELIQUIS increases the risk of bleeding and can cause serious , potentially fatal , bleeding [ see Dosage and Administration ( 2.1 ) in full Prescribing Information and Adverse Reactions ].
Concomitant use of drugs affecting hemostasis increases the risk of bleeding . These include aspirin and other antiplatelet agents , other anticoagulants , heparin , thrombolytic agents , selective serotonin reuptake inhibitors , serotonin norepinephrine reuptake inhibitors , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) [ see Drug Interactions ].
Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room . Discontinue ELIQUIS in patients with active pathological hemorrhage .
Reversal of Anticoagulant Effect
A specific antidote for ELIQUIS is not available , and there is no established way to reverse the bleeding in patients taking ELIQUIS . The pharmacodynamic effect of ELIQUIS can be expected to persist for at least 24 hours after the last dose , i . e ., for about two drug half-lives . Use of procoagulant reversal agents , such as prothrombin complex concentrate ( PCC ), activated prothrombin complex concentrate or recombinant factor VIIa , may be considered but has not been evaluated in clinical studies [ see Clinical Pharmacology ( 12.2 ) in full Prescribing Information ]. When PCCs are used , monitoring for the anticoagulation effect of apixaban using a clotting test ( PT , INR , or aPTT ) or anti-factor Xa ( FXa ) activity is not useful and is not recommended . Activated oral charcoal reduces absorption of apixaban , thereby lowering apixaban plasma concentration [ see Overdosage ].
Hemodialysis does not appear to have a substantial impact on apixaban exposure [ see Clinical Pharmacology ( 12.3 ) in full Prescribing Information ]. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban . There is no experience with antifibrinolytic agents ( tranexamic acid , aminocaproic acid ) in individuals receiving apixaban . There is no experience with systemic hemostatics ( desmopressin and aprotinin ) in individuals receiving apixaban and they are not expected to be effective as a reversal agent .
Spinal / Epidural Anesthesia or Puncture
When neuraxial anesthesia ( spinal / epidural anesthesia ) or spinal / epidural puncture is employed , patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis .
The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis . Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS . The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter . The risk may also be increased by traumatic or repeated epidural or spinal puncture . If traumatic puncture occurs , delay the administration of ELIQUIS for 48 hours .
Monitor patients frequently for signs and symptoms of neurological impairment ( e . g ., numbness or weakness of the legs , bowel , or bladder dysfunction ). If neurological compromise is noted , urgent diagnosis and treatment is necessary . Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis .
Patients with Prosthetic Heart Valves
The safety and efficacy of ELIQUIS ( apixaban ) have not been studied in patients with prosthetic heart valves . Therefore , use of ELIQUIS is not recommended in these patients .
Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy
Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy .
ADVERSE REACTIONS
The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information .
• Increased risk of thrombotic events after premature discontinuation [ see Warnings and Precautions ]
• Bleeding [ see Warnings and Precautions ]
• Spinal / epidural anesthesia or puncture [ see Warnings and Precautions ] Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice .
Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
The safety of ELIQUIS was evaluated in the ARISTOTLE and AVERROES studies [ see Clinical Studies ( 14 ) in full Prescribing Information ], including 11,284 patients exposed to ELIQUIS 5 mg twice daily and 602 patients exposed to ELIQUIS 2.5 mg twice daily . The duration of ELIQUIS exposure was ≥12 months for 9375 patients and ≥24 months for 3369 patients in the two studies . In ARISTOTLE , the mean duration of exposure was 89 weeks (> 15,000 patient-years ). In AVERROES , the mean duration of exposure was approximately 59 weeks (> 3000 patient-years ).
The most common reason for treatment discontinuation in both studies was for bleedingrelated adverse reactions ; in ARISTOTLE this occurred in 1.7 % and 2.5 % of patients treated with ELIQUIS and warfarin , respectively , and in AVERROES , in 1.5 % and 1.3 % on ELIQUIS and aspirin , respectively .
Bleeding in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE and AVERROES
Tables 1 and 2 show the number of patients experiencing major bleeding during the treatment period and the bleeding rate ( percentage of subjects with at least one bleeding event per 100 patient-years ) in ARISTOTLE and AVERROES .
Table 1 :
Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in
ARISTOTLE *
ELIQUIS N = 9088 n ( per 100 pt-year )
Warfarin N = 9052 n ( per 100 pt-year )
Hazard Ratio ( 95 % CI )
P-value
Major
327 ( 2.13 )
462 ( 3.09 )
0.69 ( 0.60 , 0.80 )
< 0.0001
Intracranial ( ICH )
52 ( 0.33 )
125 ( 0.82 )
0.41 ( 0.30 , 0.57 )
-
Hemorrhagic
38 ( 0.24 )
74 ( 0.49 )
0.51 ( 0.34 , 0.75 )
-
stroke §
Other ICH
15 ( 0.10 )
51 ( 0.34 )
0.29 ( 0.16 , 0.51 )
-
Gastrointestinal ( GI )
128 ( 0.83 )
141 ( 0.93 )
0.89 ( 0.70 , 1.14 )
-
Fatal **
10 ( 0.06 )
37 ( 0.24 )
0.27 ( 0.13 , 0.53 )
-
Intracranial
4 ( 0.03 )
30 ( 0.20 )
0.13 ( 0.05 , 0.37 )
-
Non-intracranial
6 ( 0.04 )
7 ( 0.05 )
0.84 ( 0.28 , 2.15 )
-
* Bleeding events within each subcategory were counted once per subject , but subjects
may have contributed events to multiple endpoints . Bleeding events were counted during
treatment or within 2 days of stopping study treatment ( on-treatment period ).
Defined as clinically overt bleeding accompanied by one or more of the following : a decrease
in hemoglobin of ≥2 g / dL , a transfusion of 2 or more units of packed red blood cells , bleeding
at a critical site : intracranial , intraspinal , intraocular , pericardial , intra-articular , intramuscular
with compartment syndrome , retroperitoneal or with fatal outcome .
Intracranial bleed includes intracerebral , intraventricular , subdural , and subarachnoid
bleeding . Any type of hemorrhagic stroke was adjudicated and counted as an intracranial
major bleed .
§
On-treatment analysis based on the safety population , compared to ITT analysis presented in
Section 14 .
GI bleed includes upper GI , lower GI , and rectal bleeding .
** Fatal bleeding is an adjudicated death with the primary cause of death as intracranial
bleeding or non-intracranial bleeding during the on-treatment period .
Figure 1 : Major Bleeding Hazard Ratios by Baseline Characteristics – ARISTOTLE Study
In ARISTOTLE , the results for major bleeding were generally consistent across most major subgroups including age , weight , CHADS 2 score ( a scale from 0 to 6 used to estimate risk of stroke , with higher scores predicting greater risk ), prior warfarin use , geographic region , and aspirin use at randomization ( Figure 1 ). Subjects treated with apixaban with diabetes bled more ( 3.0 % per year ) than did subjects without diabetes ( 1.9 % per year ).
Table 2 : Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in AVERROES
ELIQUIS ( apixaban ) N = 2798 n (%/ year )
Aspirin N = 2780 n (%/ year )
Hazard Ratio ( 95 % CI ) P-value
Major
45 ( 1.41 )
29 ( 0.92 )
1.54 ( 0.96 , 2.45 )
0.07
Fatal
5 ( 0.16 )
5 ( 0.16 )
0.99 ( 0.23 , 4.29 )
-
Intracranial
11 ( 0.34 )
11 ( 0.35 )
0.99 ( 0.39 , 2.51 )
-
Events associated with each endpoint were counted once per subject , but subjects may have
contributed events to multiple endpoints .
Other Adverse Reactions
Hypersensitivity reactions ( including drug hypersensitivity , such as skin rash , and anaphylactic reactions , such as allergic edema ) and syncope were reported in < 1 % of patients receiving ELIQUIS .
Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
The safety of ELIQUIS has been evaluated in 1 Phase II and 3 Phase III studies including 5924 patients exposed to ELIQUIS 2.5 mg twice daily undergoing major orthopedic surgery of the lower limbs ( elective hip replacement or elective knee replacement ) treated for up to 38 days .
In total , 11 % of the patients treated with ELIQUIS 2.5 mg twice daily experienced adverse reactions .
Bleeding results during the treatment period in the Phase III studies are shown in Table 3 . Bleeding was assessed in each study beginning with the first dose of double-blind study drug .
Table 3 : Bleeding During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery
Bleeding Endpoint *
ADVANCE-3 Hip Replacement Surgery
ELIQUIS 2.5 mg po bid 35 ± 3 days
First dose 12 to 24 hours post surgery
Enoxaparin 40 mg sc qd 35 ± 3 days
First dose 9 to 15 hours prior to surgery
ADVANCE-2 Knee Replacement Surgery
ELIQUIS 2.5 mg po bid 12 ± 2 days
First dose 12 to 24 hours post surgery
Enoxaparin 40 mg sc qd 12 ± 2 days
First dose 9 to 15 hours prior to surgery
ADVANCE-1 Knee Replacement Surgery
ELIQUIS 2.5 mg po bid 12 ± 2 days
First dose 12 to 24 hours post surgery
Enoxaparin 30 mg sc q12h 12 ± 2 days
First dose 12 to 24 hours post surgery
All treated N = 2673 N = 2659 N = 1501 N = 1508 N = 1596 N = 1588
Major ( including surgical site )
22 ( 0.82 %) 18
( 0.68 %)
n of Events / N of Patients (% per year )
Subgroup
Apixaban
Warfarin
Hazard Ratio ( 95 % CI )
All Patients
327 / 9088 ( 2.1 )
462 / 9052 ( 3.1 )
0.69 ( 0.60 , 0.80 )
Prior Warfarin / VKA Status Experienced ( 57 %)
185 / 5196 ( 2.1 )
274 / 5180 ( 3.2 )
0.66 ( 0.55 , 0.80 )
Naive ( 43 %)
142 / 3892 ( 2.2 )
188 / 3872 ( 3.0 )
0.73 ( 0.59 , 0.91 )
Age < 65 ( 30 %)
56 / 2723 ( 1.2 )
72 / 2732 ( 1.5 )
0.78 ( 0.55 , 1.11 )
≥65 and < 75 ( 39 %)
120 / 3529 ( 2.0 )
166 / 3501 ( 2.8 )
0.71 ( 0.56 , 0.89 )
≥75 ( 31 %)
151 / 2836 ( 3.3 )
224 / 2819 ( 5.2 )
0.64 ( 0.52 , 0.79 )
Sex Male ( 65 %)
225 / 5868 ( 2.3 )
294 / 5879 ( 3.0 )
0.76 ( 0.64 , 0.90 )
Female ( 35 %)
102 / 3220 ( 1.9 )
168 / 3173 ( 3.3 )
0.58 ( 0.45 , 0.74 )
Weight ≤60 kg ( 11 %)
36 / 1013 ( 2.3 )
62 / 965 ( 4.3 )
0.55 ( 0.36 , 0.83 )
> 60 kg ( 89 %)
290 / 8043 ( 2.1 )
398 / 8059 ( 3.0 )
0.72 ( 0.62 , 0.83 )
Prior Stroke or TIA Yes ( 19 %)
77 / 1687 ( 2.8 )
106 / 1735 ( 3.9 )
0.73 ( 0.54 , 0.98 )
No ( 81 %)
250 / 7401 ( 2.0 )
356 / 7317 ( 2.9 )
0.68 ( 0.58 , 0.80 )
Diabetes Mellitus Yes ( 25 %)
112 / 2276 ( 3.0 )
114 / 2250 ( 3.1 )
0.96 ( 0.74 , 1.25 )
No ( 75 %)
215 / 6812 ( 1.9 )
348 / 6802 ( 3.1 )
0.60 ( 0.51 , 0.71 )
CHADS 2 Score ≤1 ( 34 %)
76 / 3093 ( 1.4 )
126 / 3076 ( 2.3 )
0.59 ( 0.44 , 0.78 )
2 ( 36 %)
125 / 3246 ( 2.3 )
163 / 3246 ( 3.0 )
0.76 ( 0.60 , 0.96 )
≥3 ( 30 %)
126 / 2749 ( 2.9 )
173 / 2730 ( 4.1 )
0.70 ( 0.56 , 0.88 )
Creatinine Clearance < 30 mL / min ( 1 %)
7 / 136 ( 3.7 )
19 / 132 ( 11.9 )
0.32 ( 0.13 , 0.78 )
30-50 mL / min ( 15 %)
66 / 1357 ( 3.2 )
123 / 1380 ( 6.0 )
0.53 ( 0.39 , 0.71 )
> 50-80 mL / min ( 42 %)
157 / 3807 ( 2.5 )
199 / 3758 ( 3.2 )
0.76 ( 0.62 , 0.94 )
> 80 mL / min ( 41 %)
96 / 3750 ( 1.5 )
119 / 3746 ( 1.8 )
0.79 ( 0.61 , 1.04 )
Geographic Region US ( 19 %)
83 / 1716 ( 2.8 )
109 / 1693 ( 3.8 )
0.75 ( 0.56 , 1.00 )
Non-US ( 81 %)
244 / 7372 ( 2.0 )
353 / 7359 ( 2.9 )
0.68 ( 0.57 , 0.80 )
Aspirin at Randomization Yes ( 31 %)
129 / 2846 ( 2.7 )
164 / 2762 ( 3.7 )
0.75 ( 0.60 , 0.95 )
No ( 69 %)
198 / 6242 ( 1.9 )
298 / 6290 ( 2.8 )
0.66 ( 0.55 , 0.79 )
9 14 ( 0.60 %) ( 0.93 %)
11 ( 0.69 %)
22 ( 1.39 %)
Fatal
0
0
0
0
0
1 ( 0.06 %)
Hgb decrease ≥2 g / dL
13 ( 0.49 %)
10 ( 0.38 %)
8 ( 0.53 %)
9 ( 0.60 %)
10 ( 0.63 %)
16 ( 1.01 %)
Transfusion of ≥2 units RBC
16 ( 0.60 %)
14 ( 0.53 %)
5 ( 0.33 %)
9 ( 0.60 %)
9 ( 0.56 %)
18 ( 1.13 %)
Bleed at critical site §
1 ( 0.04 %)
1 ( 0.04 %)
1 ( 0.07 %)
2 ( 0.13 %)
1 ( 0.06 %)
4 ( 0.25 %)
Major + CRNM
129 ( 4.83 %)
134 ( 5.04 %)
53 ( 3.53 %)
72 ( 4.77 %)
46 ( 2.88 %)
68 ( 4.28 %)
All
313 ( 11.71 %)
334 ( 12.56 %)
104 ( 6.93 %)
126 ( 8.36 %)
85 ( 5.33 %)
108 ( 6.80 %)
* All bleeding criteria included surgical site bleeding .
Includes 13 subjects with major bleeding events that occurred before the first dose of
apixaban ( administered 12 to 24 hours post surgery ).
Includes 5 subjects with major bleeding events that occurred before the first dose of
apixaban ( administered 12 to 24 hours post surgery ).
§
Intracranial , intraspinal , intraocular , pericardial , an operated joint requiring re-operation or
intervention , intramuscular with compartment syndrome , or retroperitoneal . Bleeding into
an operated joint requiring re-operation or intervention was present in all patients with
this category of bleeding . Events and event rates include one enoxaparin-treated patient in
ADVANCE-1 who also had intracranial hemorrhage .
CRNM = clinically relevant nonmajor .
0.125 0.25 0.5 1 2
Note : The figure above presents effects in various subgroups , all of which are baseline characteristics and all of which were pre-specified , if not the groupings . The 95 % confidence limits that are shown do not take into account how many comparisons were made , nor do they reflect the effect of a particular factor after adjustment for all other factors . Apparent homogeneity or heterogeneity among groups should not be over-interpreted .
Apixaban Better
Warfarin Better
ELIQUIS® (apixaban) tablets, for oral use Brief Summary of Prescribing Information. For complete prescribing information consult official package insert. WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration, Warnings and Precautions, and Clinical Studies (14.1) in full Prescribing Information]. (B) SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between the administration of ELIQUIS and neuraxial procedures is not known [see Warnings and Precautions] Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions]. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [see Warnings and Precautions]. INDICATIONS AND USAGE Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation— ELIQUIS® (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery— ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. Treatment of Deep Vein Thrombosis—ELIQUIS is indicated for the treatment of DVT. Treatment of Pulmonary Embolism—ELIQUIS is indicated for the treatment of PE. Reduction in the Risk of Recurrence of DVT and PE—ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy. DOSAGE AND ADMINISTRATION (Selected information) Temporary Interruption for Surgery and Other Interventions ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established. (For complete Dosage and Administration section, see full Prescribing Information.) CONTRAINDICATIONS ELIQUIS is contraindicated in patients with the following conditions: • Active pathological bleeding [see Warnings and Precautions and Adverse Reactions] • Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [see Adverse Reactions] WARNINGS AND PRECAUTIONS Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.4) and Clinical Studies (14.1) in full Prescribing Information]. Bleeding ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding [see Dosage and Administration (2.1) in full Prescribing Information and Adverse Reactions]. Concomitant use of drugs ѥхͥ́ɕ͕́ѡɥͬQ͔Ց)ɥѡȁѥѕЁ̰ѡȁѥձ̰ɥѡɽѥ̰)͕ѥ͕ٔɽѽɕхѽ̰͕ɽѽɕɥɕхѽ̰)ѕɽѤѽ䁑՝̀9M%̤m͕՜%ѕɅѥt)٥͔ѥ́ͥ́ѽ́́ѼɕЁѡѕ䁽ȁѼ)ɝɽ͍ѥՔ1%EU%Lѥ́ݥѠѥٔѡɡ)IٕͅѥձЁ)ѥєȁ1%EU%ĹЁمѡɔ́х݅͡Ѽɕٕ͔ѡ)ѥ́х1%EU%LQɵ幅Ё1%EU%Lѕ)ѼͥЁȁЁЀЁ́ѕȁѡЁ͔ȁЁݼ՜̸ٕU͔)ɽձЁɕٕ̰ͅՍ́ɽѡɽɅєA ѥمѕ)ɽѡɽɅєȁɕЁѽȁY%%䁉ͥɕЁ)ЁمՅѕՑ́m͕ Aɵ䀠ȸȤձAɕ͍ɥ)%ɵѥt]A ́ɔ͕ѽɥȁѡѥձѥЁᅉ)ͥѥѕЀAP%9HȁAQPȁѤѽȁaaѥ٥䁥́Ё͕հ́)ɕѥمѕɅɍɕՍ́ͽѥᅉѡɕ䁱ݕɥ)ᅉ͵Ʌѥm͕=ٕɑͅt)!ͥ́́ЁȁѼٔՉхѥЁᅉɔm͕) Aɵ䀠ȸ̤ձAɕ͍ɥ%ɵѥtAɽхձє٥х,)ɔЁѕѼЁѡѥձЁѥ٥䁽ᅉQɔ́ɥݥѠ)ѥɥѥ̀Ʌᅵɽ٥Յ́ɕ٥ᅉ)Qɔ́ɥݥѠѕхѥ̀͵ɕͥɽѥ٥Յ)ɕ٥ᅉѡ䁅ɔЁѕѼѥٔ́ɕٕͅи)MɅѡͥȁAչɔ)]Ʌ᥅ѡͥɅѡͥȁɅչɔ́啐)ѥ́ɕѕݥѠѥѡɽѥ́ȁɕٕѥѡɽѥ́ɔ)ЁɥٕͬɅȁѽݡɕձЁѕɴȁɵ)Ʌ̸ͥ)Qɥͬѡ͔ٕ́䁉ɕ͕ѡѽɅѥ͔ٔݕɅ)ѡѕ́ȁѡхЁ͔ɽՍ́ѥх̸ͥ%ݕɅ)ȁɅѡѡѕ́͡ձЁɕٕɱȁѡЁ́ѕȁѡЁɅѥ)1%EU%LQЁ͔1%EU%L͡ձЁѕɕɱȁѡԁ́ѕȁѡ)ɕمѡѡѕȸQɥͬ䁅ͼɕ͕ɅյѥȁɕѕɅ)չɔ%Ʌյѥչɔ̰ѡɅѥ1%EU%LȀ̸)5ѽȁѥ́ɕՕѱ䁙ȁͥ́ѽ́ɽɵЀյ)ȁݕ́ѡ̰ݕȁȁ͙չѥ%ɽɽ͔́ѕ)ɝЁͥ́ɕѵЁ́ͅ丁AɥȁѼɅ᥅ѕٕѥѡͥ͡ձ)ͥȁѡѕѥЁٕ́ѡɥͬѥձѕѥ́ȁѥ́Ѽ)ѥձѕȁѡɽɽ居̸()Aѥ́ݥѠAɽѡѥ!ЁYٕ)Qͅ䁅䁽1%EU%LᅉٔЁՑѥ́ݥѠɽѡѥ)Ёم̸ٕQɕɔ͔1%EU%ĹЁɕѡ͔ѥ̸)єA!幅UхAѥ́ȁAѥ́ݡIեɔQɽͥ́)Aձѽ)%ѥѥ1%EU%ĹЁɕ́ѕɹѥٔѼչɅѥѕɥȁѡѥ)ɕѵЁѥ́ݥѠAݡɕ͕ЁݥѠ幅х䁽ȁݡɕٔ)ѡɽͥ́ȁձ䁕ѽ)YIMI Q%=9L)Qݥ͕ɥٕ͔́ɕѥ́ɔ͍͕ɕѕȁхѡȁ͕ѥ́ѡ)ɕ͍ɥɵѥ+%ɕ͕ɥͬѡɽѥٕ́ѕȁɕɔ͍ѥՅѥm͕]ɹ́)Aɕѥt+ m͕]ɹ́Aɕѥt+MɅѡͥȁչɔm͕]ɹ́Aɕѥt) Qɥ́ɥ) ͔ɥ́ɔՍѕչȁݥم她ѥ̰ٕ͔ɕѥɅѕ)͕ٕѡɥ́՜Ёɕѱ䁍ɕѼɅѕ́ѡɥ́)ѡȁ՜䁹ЁɕЁѡɅѕ͕ٕ́Ʌѥ)IՍѥIͬMɽMѕʹAѥ́ݥѠ9مձ)ɥɥѥ)Qͅ䁽1%EU%L݅́مՅѕѡI%MQ=Q1YII=LՑ́m͕ )MՑ̀ФձAɕ͍ɥ%ɵѥtՑİЁѥ͕́Ѽ1%EU%Lԁ)ݥ䁅ȁѥ͕́Ѽ1%EU%Lȸԁݥ丁QɅѥ1%EU%L)ɔ݅̃&ȁѡ́Ȁԁѥ́&Ёѡ́Ȁѥ́ѡݼ)Ց̸%I%MQ=Q1ѡɅѥɔ݅̀ݕ̀԰ѥе啅̤%)YII=LѡɅѥɔ݅́ɽ᥵ѕݕ̀ѥе啅̤)QЁɕͽȁɕѵЁ͍ѥՅѥѠՑ́݅́ȁɕѕٕ͔ɕѥ쁥I%MQ=Q1ѡ́ɕĸܔȸԔѥ́ɕѕ)ݥѠ1%EU%L݅əɥɕѥٕ䰁YII=LĸԔĸ̔1%EU%L)ɥɕѥٕ) Aѥ́ݥѠ9مձȁɥɥѥI%MQ=Q1YII=L)Q̀āȁ͡܁ѡյȁѥ́ɥȁɥѡɕѵ)ɥѡɅєɍхՉ́ݥѠЁЁٕЁȀ)ѥе啅̤I%MQ=Q1YII=L)Q()Q() ٕ́Aѥ́ݥѠ9مձȁɥɥѥYII=L()1%EU%Lᅉɥ)8)8)!ɐIѥ)啅Ȥ)啅Ȥ(Ԕ $)@مՔ)5(ԀĸĤ(䀠Ȥ(ĸЀذȸԤ()х(Ԁؤ(Ԁؤ(䀠̰и)%ɅɅ(ĀФ(ĀԤ(䀠䰀ȸĤ)ٕ́ͽѕݥѠЁݕɔչѕȁՉаЁՉ ́䁡ٔ)ɥѕٕ́Ѽձѥ̸)=ѡȁٕ͔Iѥ)!͕ͥѥ٥ɕѥ̀Ց՜͕ͥѥ٥䰁Ս́ͭɅ͠居ѥ)ɕѥ̰Ս́ɝ幍ݕɔɕѕĔѥ́ɕ٥)1%EU%L)Aɽ居́YQɽͥ́ݥ!ȁ-IЁMɝ)Qͅ䁽1%EU%ĹمՅѕāA͔%$́A͔%%$Ց́Ց(Ёѥ͕́Ѽ1%EU%Lȸԁݥչɝȁѡɝ䁽)ѡݕȁ̀ѥٔɕЁȁѥٔɕФɕѕȁѼ̸)%ѽхĔѡѥ́ɕѕݥѠ1%EU%Lȸԁݥ䁕ɥٕ͔)ɕѥ̸) ɕձ́ɥѡɕѵЁɥѡA͔%%$Ց́ɔ͡ݸQ̸) ͕͕݅́Ց䁉ݥѠѡЁ͔ՉՑ䁑՜)Q() ɥѡQɕѵЁAɥAѥ́Uɝѥٔ!)ȁ-IЁMɝ() )Ш() ٕ́Aѥ́ݥѠ9مձȁɥɥѥ)I%MQ=Q1()5ˊ)%ɅɅ% )!ɡ)ɽ )=ѡȁ% )ɽѕѥ$ )х)%ɅɅ)9ɅɅ()1%EU%L)8)(е啅Ȥ()]əɥ)8)(е啅Ȥ()!ɐIѥ(Ԕ $()@مՔ((܀ȸ̤(Ȁ̤(Ф((Ȁ̸(ԀȤ(Ѐ((䀠(Āܤ(ĀаԤ(((((Ԁ(̤(ؤ(Ѐ̤(؀Ф((ĀФ(Ā̤(܀Ф((܀Ԥ((䀠ذĤ(䀠ĸФ(܀̰̤(̀԰ܤ(ЀఀȸԤ((()ɕѕ() ٕ́ݥѡՉѕݕɔչѕȁՉаЁՉ)䁡ٔɥѕٕ́Ѽձѥ̸ ٕ́ݕɔչѕɥ)ɕѵЁȁݥѡȁ́ѽՑɕѵЀɕѵЁɥ+́䁽ٕЁ䁽ȁɔѡݥ聄ɕ͔)&ȁ0Ʌ͙ͥȁȁɔչ́ɕ̰)Ёɥѥͥє聥ɅɅɅɅձȰɥɑɄѥձȰɅ͍ձ)ݥѠѵЁ幑ɽɕɽɥѽȁݥѠхэ+%ɅɅՑ́ɅɕɅɅٕɥձȰՉɅՉɅ)ɡɽ݅́Ցѕչѕ́ɅɅ)ȁ+ =ɕѵЁ͕ͥ́ѡͅձѥɕѼ%QPͥ́ɕ͕ѕ)Mѥи+ ؁$Ց́ȁ$ݕȁ$ɕх(х́ՑѕѠݥѠѡɥ䁍͔Ѡ́ɅɅ)ȁɅɅɥѡɕѵЁɥ(()ɔ()%I%MQ=Q1ѡɕձ́ȁȁݕɔɅ䁍ͥѕЁɽ́Ё)Չɽ́Ցݕа !Lȁ͍ɔ͍ɽѼ؁͕Ѽѥєɥͬ)ɽݥѠȁ͍ɕ́ɕѥɕѕȁɥͬɥȁ݅əɥ͔Ʌɕ)ɥ͔ЁɅѥɔĤMՉ́ɕѕݥѠᅉݥѠѕ́ɔ(̸ȁ啅ȤѡՉ́ݥѡЁѕ̀ĸ䔁ȁ啅Ȥ()Y9 )Y9 )Y9 )!I)-I)-I)Mɝ)Mɝ)Mɝ)1%EU%Lɥ1%EU%Lɥ1%EU%L)ɥ(ȸԁ((ȸԁ((ȸԁ())͌Ő))͌Ő))͌ɠ( ́̀ ́̀ ȁ̀ ȁ̀ ȁ̀ ȁ)Ё͔Ё͔Ё͔Ё͔Ё͔Ё͔(ȁѼ(Ѽ(ȁѼ(Ѽ(ȁѼ(ȁѼ)́Ё́ɥȁ́Ё́ɥȁ́Ё́)ɝѼɝɝѼɝɝ)ɝ)8)8)8)88)8()5(Ցɝ)ͥє)х(((Ȕ(((((((((̔(((䔤(((ĸ䔤((((((((((()!ɕ͔+&ȁ0)QɅ͙ͥ+&ȁչ́I ) )ɥѥͥї )5( I97 )(((䔤((((Д((и̔((ĸĔ(((((̔((Д((ԸД((ȸؔ(((̔((̔((ܔ((̸̔((ظ̔(((((((̔((иܔ((ؔ(((̔((ؔ((ؔ((ȸ((Ը̔(((ؔ((ĸĔ((ĸ̔((Ԕ((и((ظ((ɥѕɥՑɝͥє+%Ց̀́Չ́ݥѠȁٕ́ѡЁɕɔѡЁ͔)ᅉѕɕȁѼЁ́Ёɝ䤸+%Ց̀ԁՉ́ݥѠȁٕ́ѡЁɕɔѡЁ͔)ᅉѕɕȁѼЁ́Ёɝ䤸+ %ɅɅɅɅձȰɥɑɅѕЁɕեɥɔɅѥ)ѕٕѥɅ͍ձȁݥѠѵЁ幑ɽȁɕɽɥѽ Ѽ)ɅѕЁɕեɥɔɅѥȁѕٕѥ݅́ɕ͕Ёѥ́ݥѠ)ѡ́ѕ䁽ٕٕ́ЁɅѕ́ՑɥɕѕѥЁ)Y9 āݡͼɅɅɡ+ ؁ I94􁍱ɕمЁȸ()5ȁ !ɐIѥ́ ͕ Ʌѕɥѥ̃LI%MQ=Q1MՑ()ٕ̀8Aѥ̀ȁ啅Ȥ)MՉɽ)Aѥ)Aɥȁ]əɥY-Mх)ɥܔ)9ٔ̔)(Ԁ+&ԁԀ䔤+&ԀĔ)M)5Ԕ)Ԕ)]+&Ĕ(䔤)AɥȁMɽȁQ%)è䔤)9Ĕ)ѕ́5)èԔ)9Ԕ) !LȁMɔ+&ĀД(Ȁؔ+&̀) ɕѥ Ʌ(0Ĕ(0Ԕ(0Ȕ(0Ĕ)ɅI)UL䔤)9ULĔ)ɥЁIѥ)èĔ)9䔤()ᅉ(܀ȸĤ()]əɥ(ȀȀ̸Ĥ()!ɐIѥԔ $(䀠((Ԁ؀ȸĤ(ȀȀȸȤ((Ѐ̸Ȥ(Ȁ̸((؀԰(̀䰀Ĥ((؀̀ĸȤ(䀠ȸ(Ā؀̸̤((ȀȀĸԤ(؀Āȸ (Ѐ䀠ԸȤ((԰ĸĤ(Āذ(ЀȰ((Ԁȸ̤(Ȁĸ((Ѐ䀠̸(̸̤̀((؀а(԰Ф((؀̀ȸ̤(̀ȸĤ((ȀԀи̤(䀠̸((Ԁذ̤(ȀȰ̤((܀܀ȸ(Āȸ((؀Ԁ̸(؀܀ȸ((̀а(ఀ((Ȁ؀̸(ԀȀĸ((Ѐ̸Ĥ(Ȁ̸Ĥ((؀аĸԤ(İĤ((؀̀ĸФ(Ԁ؀ȸ̤(؀䀠ȸ((؀؀ȸ̤(̀؀̸(̀иĤ((䀠а(؀ؤ(ذ((܀؀̸ܤ(؀܀̸Ȥ(܀܀ȸԤ(؀ĸԤ((䀼Ȁĸ(̀ظ(䀼̸Ȥ(䀼؀ĸ((Ȁ̰(̀䰀Ĥ(؀ȰФ(䀠İĸФ((̀؀ȸ(ЀȀȸ((䀼̸̀(̀䀠ȸ((Ԁذĸ(ܰ((䀼؀ȸܤ(Ȁĸ((ЀȀ̸ܤ(ȸ((ԀԤ(؀԰(((((()ᅉ) ѕ(((()]əɥ) ѕ()9єQɔٔɕ͕́́مɥ́Չɽ̰ݡɔ͕Ʌѕɥѥ́ݡݕɔɔЁѡɽ̸QԔ́ѡЁɔ)͡ݸЁхѼչЁ܁䁍ɥͽ́ݕɔȁѡɕЁѡЁѥձȁѽȁѕȁѵЁȁѡȁѽ̸ɕЁ䁽ȁѕɽ)ɽ́͡ձЁٕȵѕɕѕ((0